

Non- Tuberculous Mycobacterial Infections Market to Show Remarkable Growth Trends from 2023 to 2034, DelveInsight Report

Non- Tuberculous Mycobacterial Infections Market Forecast report offers an in-depth insight of forecasted epidemiology as well as the market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES,
December 17, 2024 /

EINPresswire.com/ -- The Non-Tuberculous Mycobacterial Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non- Tuberculous Mycobacterial Infections pipeline products will significantly revolutionize the Non- Tuberculous Mycobacterial Infections market dynamics.



Non- Tuberculous Mycobacterial Infections Market Insights

DelveInsight's "Non- Tuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Non- Tuberculous Mycobacterial Infections, historical and forecasted epidemiology as well as the Non- Tuberculous Mycobacterial Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Non- Tuberculous Mycobacterial Infections market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Non- Tuberculous Mycobacterial Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Non- Tuberculous Mycobacterial Infections Market Forecast](#)

Some of the key facts of the Non- Tuberculous Mycobacterial Infections Market Report:

- The Non- Tuberculous Mycobacterial Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- Based on DelveInsight's epidemiology model, the total number of diagnosed prevalent cases of Nontuberculous Mycobacterial Infections in the US was around 108,000 in 2023, with an anticipated increase during the forecast period (2024–2034) due to various contributing factors.
- In 2023, NTM Infections in the US showed a higher prevalence in females compared to males. Females represented about 68% of the total diagnosed prevalent cases of Nontuberculous Mycobacterial Infections, while males accounted for around 32%.
- In 2023, *M. avium* was the most common species responsible for Nontuberculous Mycobacterial Infections in the US, accounting for nearly 76 thousand diagnosed prevalent cases. It was followed by *M. abscessus* with around 14 thousand cases, and other species like *M. kansasii* and *M. xenopi*, which contributed to approximately 18 thousand cases.
- In 2023, the US had about 86 thousand diagnosed prevalent cases of Nontuberculous Mycobacterial Infections of the pulmonary type and approximately 22 thousand cases of the extrapulmonary type
- As per Shanmugam et al., about 1.5 million people died from TB, and nearly 10 million people fall ill with *Mtb* infection worldwide, of which only 6.4 million were diagnosed and officially reported
- Among the 7MM countries. The most prevalent cases of Non- Tuberculous Mycobacterial infections were recorded in the United States.
- Key Non- Tuberculous Mycobacterial Infections Companies: Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
- Key Non- Tuberculous Mycobacterial Infections Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others

Non- Tuberculous Mycobacterial Infections Overview

According to Centers for Disease Control and Prevention (CDC), NTM are also referred to as atypical mycobacteria, mycobacteria other than tuberculosis (MOTT), or environmental mycobacteria. It is a ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy persons and those with compromised immune systems.

Get a Free sample for the Non- Tuberculous Mycobacterial Infections Market Report:

https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Non- Tuberculous Mycobacterial Infections Market

The dynamics of the Non- Tuberculous Mycobacterial Infections market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“Of the Non- Tuberculous Mycobacterial Infections emerging therapies, the most anticipated product to get launched is aminoglycoside antibacterial, Arikayce (amikacin). Apart from this,

other products include RHB-204, Thiolanox, Molgradex, and Nitric Oxide. Some of these products have also received Qualified Infectious Disease Product (QIDP), Fastrack Designations and Orphan Designations.”

Non- Tuberculous Mycobacterial Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non- Tuberculous Mycobacterial Infections Epidemiology Segmentation:

The Non- Tuberculous Mycobacterial Infections market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Prevalence of Non- Tuberculous Mycobacterial Infections
- Prevalent Cases of Non- Tuberculous Mycobacterial Infections by severity
- Gender-specific Prevalence of Non- Tuberculous Mycobacterial Infections
- Diagnosed Cases of Episodic and Chronic Non- Tuberculous Mycobacterial Infections

Download the report to understand which factors are driving Non- Tuberculous Mycobacterial Infections epidemiology trends @ [Non- Tuberculous Mycobacterial Infections Epidemiological Insights](#)

Non- Tuberculous Mycobacterial Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non- Tuberculous Mycobacterial Infections market or expected to get launched during the study period. The analysis covers Non- Tuberculous Mycobacterial Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non- Tuberculous Mycobacterial Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non- Tuberculous Mycobacterial Infections Therapies and Key Companies

- SPR720: Spero Therapeutics
- Molgramostim: Savara Pharmaceuticals
- Thiolanox (Nitric Oxide): Mallinckrodt Inc.
- NUZYRA (omadacycline): Paratek Pharmaceuticals Inc.
- CYT 107: Revimmune

Non- Tuberculous Mycobacterial Infections Market Drivers

- There is increase in spending on branded drugs
- Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of NTM infections

Non- Tuberculous Mycobacterial Infections Market Unmet Needs

- Challenges in diagnoses
- Development of novel therapies
- Lack of awareness
- Poor disease understanding
- Clinical biomarkers

Scope of the Non- Tuberculous Mycobacterial Infections Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Non- Tuberculous Mycobacterial Infections Companies: Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others
- Key Non- Tuberculous Mycobacterial Infections Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others
- Non- Tuberculous Mycobacterial Infections Therapeutic Assessment: Non- Tuberculous Mycobacterial Infections current marketed and Non- Tuberculous Mycobacterial Infections emerging therapies
- Non- Tuberculous Mycobacterial Infections Market Dynamics: Non- Tuberculous Mycobacterial Infections market drivers and Non- Tuberculous Mycobacterial Infections market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Non- Tuberculous Mycobacterial Infections Unmet Needs, KOL's views, Analyst's views, Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement

Discover more about therapies set to grab major Non- Tuberculous Mycobacterial Infections market share @ [Non- Tuberculous Mycobacterial Infections Treatment Landscape](#)

Table of Contents

1. Non- Tuberculous Mycobacterial Infections Market Report Introduction
2. Executive Summary for Non- Tuberculous Mycobacterial Infections
3. SWOT analysis of Non- Tuberculous Mycobacterial Infections
4. Non- Tuberculous Mycobacterial Infections Patient Share (%) Overview at a Glance
5. Non- Tuberculous Mycobacterial Infections Market Overview at a Glance
6. Non- Tuberculous Mycobacterial Infections Disease Background and Overview
7. Non- Tuberculous Mycobacterial Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Non- Tuberculous Mycobacterial Infections

9. Non- Tuberculous Mycobacterial Infections Current Treatment and Medical Practices
10. Non- Tuberculous Mycobacterial Infections Unmet Needs
11. Non- Tuberculous Mycobacterial Infections Emerging Therapies
12. Non- Tuberculous Mycobacterial Infections Market Outlook
13. Country-Wise Non- Tuberculous Mycobacterial Infections Market Analysis (2020–2034)
14. Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement of Therapies
15. Non- Tuberculous Mycobacterial Infections Market Drivers
16. Non- Tuberculous Mycobacterial Infections Market Barriers
17. Non- Tuberculous Mycobacterial Infections Appendix
18. Non- Tuberculous Mycobacterial Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/769676286>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.